Standard BioTools Announces Conference Call and Webcast of Third Quarter 2023 Financial Results on November 7, 2023
25 Outubro 2023 - 9:30AM
Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose
– Unleashing tools to accelerate breakthroughs in human health –
today announced that it will report third quarter 2023 financial
results on Tuesday, November 7, 2023, after the close of the
market.
The Company’s management will host a conference call and webcast
at 1:30 p.m. PT, 4:30 p.m. ET, on November 7, 2023, to discuss
third quarter 2023 financial results and operational progress. A
press release including the financial results will be publicly
distributed before the call.
Individuals interested in listening to the conference call may
do so by dialing:
US domestic callers: (888) 346-3970Outside US
callers: (412) 902-4297
Live audio of the webcast will be available online on the
Investor Relations page of the Company’s website at Events
& Presentations. The webcast will be archived and available on
Standard BioTools™ Investor Relations page
at investors.standardbio.com.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq:LAB), previously known as
Fluidigm Corporation, is driven by a bold purpose – Unleashing
tools to accelerate breakthroughs in human health. Standard
BioTools has an established portfolio of essential, standardized
next-generation technologies that help biomedical researchers
develop medicines faster and better. As a leading solutions
provider, the company provides reliable and repeatable insights in
health and disease using its proprietary mass cytometry and
microfluidics technologies, which help transform scientific
discoveries into better patient outcomes. Standard BioTools works
with leading academic, government, pharmaceutical, biotechnology,
plant and animal research, and clinical laboratories worldwide,
focusing on the most pressing needs in translational and clinical
research, including oncology, immunology, and immunotherapy. Learn
more at www.standardbio.com or connect with us on Twitter®,
Facebook®, LinkedIn, and YouTube™. Standard BioTools, the Standard
BioTools logo, Fluidigm, the Fluidigm logo, and “Unleashing tools
to accelerate breakthroughs in human health” are trademarks and/or
registered trademarks of Standard BioTools Inc. or its affiliates
in the United States and/or other countries. All other trademarks
are the sole property of their respective owners. Standard
BioTools products are provided for Research Use
Only. Not for use in diagnostic procedures.
Available Information
Standard BioTools uses its website (standardbio.com),
investor site (investors.standardbio.com), corporate Twitter
account (@Standard_BioT), Facebook page
(facebook.com/StandardBioT), and LinkedIn page
(linkedin.com/company/standard-biotools) as channels of
distribution of information about its products, its planned
financial and other announcements, its attendance at upcoming
investor and industry conferences, and other matters. Such
information may be deemed material information, and Standard
BioTools may use these channels to comply with its disclosure
obligations under Regulation FD. Therefore, investors should
monitor Standard BioTools’ website and its social media accounts in
addition to following its press releases, SEC filings,
public conference calls, and webcasts.
Investor Contact:
Peter DeNardo 415 389
6400 ir@standardbio.com
Standard BioTools (NASDAQ:LAB)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Standard BioTools (NASDAQ:LAB)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024